cannabidiol (Cardiol Therapeutics)

大麻二酚 (Cardiol Therapeutics)

Report date: 2024/04/25 17:31:16

Base Information

Drug Namecannabidiol (Cardiol Therapeutics)
Drug Alias NameCardiolRx™CardiolRx™100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor inverse agonistsCannabinoid CB1 receptor inverse agonistsSerotonin 5-HT1 receptors modulators +[4] 
TargetsCannabinoid CB2 receptorCannabinoid CB1 receptorSerotonin 5-HT1 receptors +[4] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)PericarditisMyocarditis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMexico +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCardiol Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCardiol Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)PericarditisMyocarditis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A